The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: A review

被引:42
作者
Grinblat, Beni [1 ]
Scheinberg, Morton [2 ]
机构
[1] Hosp Israelita Albert Einstein, Sao Paulo, Brazil
[2] Hosp Israelita Albert Einstein & Res Inst, Sao Paulo, Brazil
关键词
psoriasis; psoriatic arthritis; anti TNF agents;
D O I
10.1016/j.semarthrit.2007.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: The paradoxical observation that antitumor necrosis factor (anti-TNF) agents are capable of inducing psoriasis and psoriasiform skin lesions while also being therapy for psoriasis gained substantial support following the description of this condition by several authors. Our aim was to review the literature of this subject. Methods: A retrospective review of the literature was performed using the Medline database between 2005 and February 2007. Results: Since the first publication by our group in April 2005 to the present, 50 cases of this type of dermatitis have been described. More than half of the cases were associated with the use of infliximab. Different presentations of psoriasis were reported, plaque form being the most prevalent. A number of clinical and immunological observations suggest a cytokine disequilibrium in patients receiving chronic anti-TNF therapy leading to this condition. Treatment for the skin disease includes changing the anti-TNF agent or discontinuing the medication. Conclusions: The appearance of psoriasis and psoriasiform lesions during chronic anti-TNF therapy is dependent on the presence of known and unknown interrelated factors. Enhanced clinician awareness of this drug complication and further investigation of its mechanisms are warranted. (c) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:251 / 255
页数:5
相关论文
共 44 条
[31]   A medical conundrum: onset of psoriasis in patients receiving antitumour necrosis factor agents [J].
Ritchlin, C. ;
Tausk, F. .
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (12) :1541-1544
[32]  
Roux CH, 2007, J RHEUMATOL, V34, P434
[33]  
Saissi EH, 2003, ANN DERMATOL VENER, V130, P612
[34]   Monoclonal antibodies in the treatment of rheumatoid arthritis: toward a therapeutic revolution. [J].
Sany, Jacques .
COMPTES RENDUS BIOLOGIES, 2006, 329 (04) :228-240
[35]  
Sari I, 2006, J RHEUMATOL, V33, P1411
[36]   Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection [J].
Seçkin, D ;
Durusoy, Ç ;
Sahin, S .
PEDIATRIC DERMATOLOGY, 2004, 21 (05) :577-579
[37]   Psoriasis induced by anti-tumor necrosis factor therapy - A paradoxical adverse reaction [J].
Sfikakis, PP ;
Iliopoulos, A ;
Elezoglou, A ;
Kittas, C ;
Stratigos, A .
ARTHRITIS AND RHEUMATISM, 2005, 52 (08) :2513-2518
[38]  
Skov L, 2000, CLIN EXP DERMATOL, V25, P57
[39]   PUSTULAR ERUPTION AFTER DRUG EXPOSURE - IS IT PUSTULAR PSORIASIS OR A PUSTULAR DRUG ERUPTION [J].
SPENCER, JM ;
SILVERS, DN ;
GROSSMAN, ME .
BRITISH JOURNAL OF DERMATOLOGY, 1994, 130 (04) :514-519
[40]   Cutaneous adverse events of biological therapy for psoriasis: Review of the literature [J].
Thielen, AM ;
Kuenzli, S ;
Saurat, JH .
DERMATOLOGY, 2005, 211 (03) :209-217